Boston Scientific Q2 FY2026: sales up 7.5%, adjusted EPS $0.86
Boston Scientific beat its own guidance in Q2 FY2026: sales of $5.442 billion, gross margin of 70.7% and adjusted EPS of $0.86, about two cents above the $0.8354 consensus estimate. The offset is the outlook — management guides third-quarter growth of 3 to 5 percent, below the 7.5 percent just delivered. That split is why the verdict here is Neutral. Below, we separate what actually happened from what management now expects.
1 · Expected vs. Actual
Free preview belowGAAP EPS of $0.61 was up from $0.53 a year ago, and adjusted EPS of $0.86 beat both the $0.82-$0.84 guidance range and the $0.8354 consensus estimate. The gap between GAAP and adjusted is wide: adjusted excludes $0.14 of amortization, $0.05 of acquisition-related charges, $0.04 of litigation charges, $0.02 of restructuring, a $0.05 deferred tax expense and a $0.05 IEEPA tariff refund. Read adjusted EPS as a measure of operating momentum, not of cash earnings.
Revenue of $5.442 billion rose 7.5% on a reported basis and 7.0% on an operational and organic basis against a guidance range of 5.5 to 7.5 percent reported and 5 to 7 percent organic, so the quarter landed at or above the top of the range. Gross margin of 70.7% compares with 67.7% in the same quarter a year earlier, a 3.0 point improvement. Cardiovascular grew 8.3% reported while MedSurg grew 5.9%, so the heart-and-vascular side did the heavy lifting.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.